SIGNS THAT KEYTRUDA IS WORKING
The effectiveness of Keytruda (pembrolizumab) treatment can be evaluated by monitoring various clinical markers, including tumor response, changes in the size of the tumor(s), progression-free survival, and overall survival.
Some of the signs that Keytruda is working include:
A decrease in the size of the tumor(s) as seen on imaging studies (such as CT or MRI scans)
A decrease in the level of cancer markers in the blood or tumor tissue
An increase in the number of immune cells (such as T cells) in the blood and in the tumor microenvironment
A decrease in symptoms associated with the cancer, such as pain, fatigue, or difficulty breathing
An improvement in overall quality of life
Progression-free survival and overall survival are prolonged, compared to not receiving the treatment or receiving other treatments.
It's worth noting that response to the treatment may vary depending on the cancer type, patient's genetic profile and PD-L1 expression. Also, it's important to consult with an experienced oncologist and closely monitor the patient's response to the treatment and manage any side effects that may occur. Your healthcare provider will schedule regular follow-up visits and imaging to track the progression of the disease, and adjust treatment as necessary.
KEYTRUDA LONG TERM SIDE EFFECTS
Keytruda (pembrolizumab) is a relatively new treatment and long-term side effects are still being studied. Most of the side effects associated with Keytruda occur in the short-term and are manageable, but it is important to be aware that some long-term side effects may also occur. The most common long-term side effects are not yet well known but based on current data, some of the potential long-term side effects include:
Chronic inflammation: Keytruda works by activating the immune system to attack cancer cells, which can lead to chronic inflammation in some patients, particularly in the lungs, gut, or other organs.
Autoimmune disorders: Keytruda can cause the immune system to attack healthy cells and tissue, which can lead to autoimmune disorders such as lupus or rheumatoid arthritis.
Secondary malignancies: There have been reported cases of secondary malignancies including non-melanoma skin cancer, lung cancer and head and neck cancer following treatment with keytruda.
It's important to keep in mind that these long-term side effects are relatively rare and the benefits of Keytruda generally outweigh the risks, but it is still important to be aware of them. Also, it's important to keep in mind that the long-term side effects of Keytruda are not completely understood yet, as the drug is relatively new, and more research is needed to fully understand its long-term safety profile. It's crucial to discuss the potential benefits and risks with your healthcare provider before starting the treatment and to closely monitor the patient's response to the treatment and manage any side effects that may occur.
0 Comments